Laquinimod in Participants With Relapsing-Remitting Multiple Sclerosis with Avonex® Reference Arm

Study Title

BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon ־²-1a (Avonexֲ®)

Teva Identifier

MS-LAQ-302 | EUDRACT 2007-005450-23

ClinicalTrials.gov Identifier

NCT00605215

Study Status

Completed

Trial Condition(s)

Multiple Sclerosis

Interventions

Drug: laquinimod | Drug: placebo | Drug: Interferon ־²-1a (Avonexֲ®)

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
ClinicalTrials.gov study records with inclusion and exclusion criteria
neurology icon for clinical trials

Key Participation Requirements

Gender

Female, Male

Age Range

18 Years to 55 Years

Trial Duration

04/01/2008 - 12/01/2011

Phase

Phase 3

Study Type

Interventional